Platinum-amine compounds: importance of the labile and inert ligands for their pharmacological activities toward L1210 leukemia cells.
A series of Pt-amine compounds was assayed for their ability to inhibit the growth of cultured L1210 leukemia cells [median inhibitory dose (lD50)], their toxicity in mice [highest nonlethal dose in healthy mice (LD0)], their antitumor activity against leukemia L1210 cells grafted intraperitoneally into mice [mean survival of treated leukemic mice:mean survival of untreated leukemic mice (T/C)], and the ability to hydrolyze their labile ligands in vitro [hydrolysis half-time (t1/2)]. All Pt compounds exhibiting antitumor activity had a pair of labile ligands in the cis geometry with different charges, and the leaving groups had a wide range of hydrolysis rates. Among the compounds that showed antitumor activity, ID50 depended more on the inert ligands than on the labile ligands and was correlated with T/C. A relationship between LD0 and t1/2 was verified in the series of cis-Pt(II) compounds with the exception of the oxalate derivatives. Pt(II) and Pt(IV) compounds exhibited similar ID50, LD0, and T/C.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D006868:Hydrolysis; D007536:Isomerism; D007939:Leukemia L1210 / Q000188:drug therapy*; D008024:Ligands; D051379:Mice; D010984:Platinum / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D013329:Structure-Activity Relationship
D008024:Ligands; D010984:Platinum